Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 7, 2011While millions of women are experiencing symptoms that could indicate a serious bleeding disorder, nearly half of them are not discussing those symptoms with their healthcare provider, according to new survey findings.
07 Jun 2011 While millions of women are experiencing symptoms that could indicate a serious bleeding disorder, nearly half of them are not discussing those symptoms with their healthcare provider,...
-
May 31, 2011CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
31 May 2011 CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation...
-
May 20, 2011
Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at...
-
May 17, 2011The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases."
17 May 2011 CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX:CSL), is a recipient of the National...
-
May 2, 2011CSL Behring today honored the achievements of six scientists with the inaugural 2011 Interlaken Leadership Awards for advancing medical research and knowledge about the potential role of immunoglobulin therapy for the treatment of neurological disorders. The total value of the six awards is estimated to be more than $1.2 million.
02 May 2011 CSL Behring today honored the achievements of six scientists with the inaugural 2011 Interlaken Leadership Awards for advancing medical research and knowledge about the potential role...
-
Apr 21, 2011CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra® (Human Normal Immunoglobulin), 20 percent solution for subcutaneous injection, for treating patients diagnosed with primary immunodeficiency (PI) as well as secondary immunodeficiencies. This authorization is valid for all 29 European/European Economic Area member states.
21 Apr 2011 CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra® (Human Normal Immunoglobulin), 20 percent solution for subcutaneous...
-
Apr 20, 2011Thought leaders from the medical, scientific and patient advocacy communities gathered in New York and London for CSL Behring's Key Issues Dialogue–Immunoglobulin to examine challenges facing patients with primary immunodeficiencies.
20 Apr 2011 in New York and London for CSL Behring's Key Issues Dialogue–Immunoglobulin to examine challenges facing patients with primary immunodeficiencies. They found common ground between...
-
Apr 19, 2011CSL Behring’s capacity to produce Hizentra, a key product in its global immunoglobulin portfolio, has more than doubled following U.S. Food and Drug Administration (FDA) approval of the company’s high tech production facility in Bern, Switzerland, where Hizentra is produced.
19 Apr 2011 CSL Behring's capacity to produce Hizentra® a key product in its global immunoglobulin portfolio, has more than doubled following U.S. Food and Drug Administration (FDA) approval of...
-
Apr 19, 2011For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can pass illnesses back and forth. The Centers for Disease Control and Prevention estimates that children have about two to nine illnesses per year, nearly double the number of colds adolescents and adults experience during the same timeframe.
19 Apr 2011 For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can...
-
Apr 15, 2011CSL Behring, a world leader in the development of plasma-derived and recombinant therapeutics, today announced the winners of this year’s prestigious CSL Behring Prof. Heimburger Award 2011. The announcement coincides with World Hemophilia Day and reflects this year’s theme to "Be Inspired, Get Involved in Treatment for All.
15 Apr 2011 CSL Behring, a world leader in the development of plasma-derived and recombinant therapeutics, today announced the winners of this year’s prestigious CSL Behring – Prof. Heimburger...